The Board of Malin Corporation plc is comprised of 7 Directors, of whom 2 have executive functions.
Donal O’Connor is currently a Non-Executive Director of Perrigo Company PLC and Theravance Biopharma, Inc. Mr O’Connor previously held a number of positions at partner level in Pricewaterhouse Coopers (PwC) Ireland, including serving as Senior Partner from 1995 until 2007. He also served as a member of PwC Global Board from 2003 to 2008.
Dr. Adrian Howd has held both sell-side and buy-side roles, being a highly ranked sell-side analyst at Berenberg, Nomura and ABN Amro where he was Global Head of Healthcare Research. He also gained buy-side experience running a healthcare portfolio as part of the Principal Strategies Group at ABN Amro. Dr. Howd also served as Executive Vice President, Head of Neuroscience and Corporate Development at Evotec AG. Dr. Howd has a Ph.D in molecular neuroscience from the University of London.
Darragh Lyons is a chartered accountant and worked in a number of senior finance positions in Elan, most recently serving as the Head of Group Finance (prior to the sale of Elan to Perrigo) where he was responsible for all aspects of internal and external reporting as well as overseeing the transactional and financing activities of the company. Prior to joining Elan, Mr. Lyons worked with PricewaterhouseCoopers in Dublin, the United States and Canada, and also served in the firm’s Global Technical Accounting Group.
Liam Daniel is a non-executive director of Horizon Pharma plc since September 2014 and was President of the Institute of Directors in Ireland from 2013 to 2015 having been elected to the Board of that Institute in June 2010. He served with Elan from 1993 until 2014 in various roles including Controller, Company Secretary, Executive Vice President and as an Executive Director. Following Elan’s acquisition by Perrigo Company in December 2013, Mr. Daniel retired from Elan in March 2014. He is a graduate of University College Dublin, a Fellow of Chartered Accountants Ireland and a Chartered Director.
Owen Hughes currently serves as Managing Director of MPM Capital and as Chief Executive Officer of Cullinan Oncology, a portfolio company of the UBS Oncology Impact Fund managed by MPM Capital, which is focused on developing high value cancer therapeutics. Prior to this Mr Hughes was Chief Business Officer and head of Corporate Development at Intarcia Therapeutics, a late stage diabetes company. He is also a director of Radius Health, an osteoporosis company seeking regulatory approval for its lead product candidate. Prior to Intarcia, Mr Hughes served as a director at Brookside Capital, a multibillion-dollar hedge fund that falls under the Bain Capital umbrella. There, Mr Hughes co-managed public and private healthcare investments including those in the biotechnology, medtech and services segments. Mr Hughes has over 16 years of Wall Street experience on both the buy and sell-side.
Robert Ingram is the former CEO/chairman of GlaxoWellcome where he co-led the merger and integration that formed GlaxoSmithKline, the world’s second largest pharmaceutical company. He currently serves as a general partner of Hatteras Venture Partners. He previously served as chairman of Elan from 2010 until its sale to Perrigo Company in December 2013. Mr. Ingram was asked by former US President George H.W. Bush to form and chair the CEO Roundtable on cancer, and he was awarded the Martin Luther King, Jr. Legacy Award for International Service in January 2004.
Kieran McGowan was chief executive of the Industrial Development Authority of Ireland From 1990 until his retirement in December 1998. Up until May 2012, he was chairman of CRH plc, and has sat on the board of a number of private companies. Mr. McGowan is also a past director of Elan Corporation plc from December 1998 to its sale to Perrigo Company in December 2013. He has served as president of the Irish Management Institute and has chaired the Governing Authority at University College Dublin.